Abstract

Caspase-4 (CASP4) is a member of the inflammatory caspase subfamily and promotes inflammation. Here, we report that CASP4 in lung adenocarcinoma cells contributes to both tumor progression via angiogenesis and tumor hyperkinesis and tumor cell killing in response to high interferon (IFN)-γ levels. We observe that elevated CASP4 expression in the primary tumor is associated with cancer progression in patients with lung adenocarcinoma. Further, CASP4 knockout attenuates tumor angiogenesis and metastasis in subcutaneous tumor mouse models. CASP4 enhances the expression of genes associated with angiogenesis and cell migration in lung adenocarcinoma cell lines through nuclear factor kappa-light chain-enhancer of activated B cell signaling without stimulation by lipopolysaccharide or tumor necrosis factor. CASP4 is induced by endoplasmic reticulum stress or IFN-γ via signal transducer and activator of transcription 1. Most notably, lung adenocarcinoma cells with high CASP4 expression are more prone to IFN-γ-induced pyroptosis than those with low CASP4 expression. Our findings indicate that the CASP4 level in primary lung adenocarcinoma can predict metastasis and responsiveness to high-dose IFN-γ therapy due to cancer cell pyroptosis.

Our findings indicate that the CASP4 level in primary lung adenocarcinoma can predict metastasis and responsiveness to high-dose IFN-γ therapy due to cancer cell pyroptosis.

Details

Title
Caspase-4 promotes metastasis and interferon-γ-induced pyroptosis in lung adenocarcinoma
Author
Chiba, Yosuke 1   VIAFID ORCID Logo  ; Doi, Tomomitsu 2 ; Obayashi, Kunie 2 ; Sumida, Kazuhiro 2   VIAFID ORCID Logo  ; Nagasaka, Shohei 2 ; Wang, Ke-Yong 3 ; Yamasaki, Kei 4 ; Masago, Katsuhiro 5 ; Matsushita, Hirokazu 6 ; Kuroda, Hiroaki 7 ; Yatera, Kazuhiro 4 ; Endo, Motoyoshi 2   VIAFID ORCID Logo 

 Japan, Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913); Japan, Department of Molecular Biology, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913) 
 Japan, Department of Molecular Biology, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913) 
 Japan, Shared-Use Research Center, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913) 
 Japan, Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913) 
 Aichi Cancer Center Hospital, Department of Pathology and Molecular Diagnostics, Nagoya, Japan (GRID:grid.410800.d) (ISNI:0000 0001 0722 8444) 
 Aichi Cancer Center Research Institute, Division of Translational Oncoimmunology, Nagoya, Japan (GRID:grid.410800.d) (ISNI:0000 0001 0722 8444) 
 Teikyo University Mizonokuchi Hospital, Department of Surgery, Kawasaki, Japan (GRID:grid.264706.1) (ISNI:0000 0000 9239 9995) 
Pages
699
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3065504843
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.